Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.54 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839601 | 0.91 | MAPK14 (1.00) | MAPK14CYP3A4CSNK1DCSNK1E | |
| SCHEMBL4830346 | 0.76 | MAPK14 (0.73) | MAPK14CYP3A4CSNK1DCSNK1E | |
| SCHEMBL3827667 | 0.75 | ALDH1A1 (0.58) | MAPK14 | |
| SCHEMBL5682985 | 0.74 | BACE1 (0.52) | MAPK14 | |
| SCHEMBL5772038 | 0.74 | CYP3A4 (0.54) | MAPK14CYP3A4 | |
| SCHEMBL6210984 | 0.73 | MAPK14 (0.60) | MAPK14CYP3A4CSNK1DCSNK1E | |
| SCHEMBL5679180 | 0.73 | TAAR1 (0.50) | MAPK14 | |
| SCHEMBL7659118 | 0.72 | ALDH1A1 (0.54) | CYP3A4 | |
| SCHEMBL4838574 | 0.71 | MAPK14 (1.00) | MAPK14CYP3A4 | |
| SCHEMBL17002318 | 0.70 | MAPK14 (1.00) | MAPK14CSNK1DCSNK1EMAPK13RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320995-B2 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1554272-B1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | LILLY CO ELI (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | EIL LILLY AND COMPANY (US) | 2005-12-08 | — | — | US | disclosed |
| EP-1554272-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004014900-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | MAP3K8, MAPK8, MAPK1 | MAPK14 10/4885CYP3A4 2862/4885CSNK1D 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.